UGT2B17 CRISPR/Cas9 KO Plasmid (h2): sc-405611-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UGT2B17 CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UGT2B17 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UGT2B17 CRISPR/Cas9 KO Plasmid (h2) | sc-405611-KO-2 | 20 µg | $397.00 |
Overview
UGT2B17 encodes a UDP-glucuronosyltransferase that catalyzes phase II glucuronidation of diverse endogenous and xenobiotic substrates, increasing their solubility and promoting clearance. This enzyme contributes to steroid hormone and bile acid homeostasis and can modulate cellular exposure to bioactive and potentially toxic metabolites through hepatic and extrahepatic metabolism. Variation in UGT2B17 expression or copy number has been linked to inter-individual differences in androgen conjugation and drug metabolism phenotypes, with implications for endocrine-related biology and pharmacogenomic research. In experimental systems, UGT2B17 activity intersects with detoxification networks and influences metabolite-driven signaling responses.
UGT2B17 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the UGT2B17 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UGT2B17 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UGT2B17 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UGT2B17 protein expression.
This CRISPR knockout system enables efficient generation of UGT2B17-deficient cell models for investigation of UGT2B17 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UGT2B17 exon(s) critical for UGT2B17 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UGT2B17 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UGT2B17 CRISPR/Cas9 KO Plasmid (h) and UGT2B17 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UGT2B17 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UGT2B17 HDR Plasmid (h) and UGT2B17 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UGT2B17 homology arms to support homology-directed repair at defined UGT2B17 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.